The phase I study also revealed a high inhibition of tumor growth at the end of a 21-day dosing period with regorafenib for renal cell carcinoma cell lines characterized by increased synthesis of VEGF [24]. The gene discussed is VEGFA; the disease is renal cell carcinoma.